U.S. Stock Market Movement: ImmunityBio Surges on October 2nd as Funds Are Optimistic and ANKTIVA Expands

ImmunityBio October 2 Surge Explained

Keywords: Fund optimism, ANKTIVA expansion

1. On September 30, the GA-Courtenay Special Opportunities Fund highlighted ImmunityBio in its Q2 2026 investor letter, estimating ANKTIVA's annual potential market size at over $580 million. If approved for lung cancer indications, the potential market size could exceed $4.3 billion.

2. As of September 30, ANKTIVA has been approved or authorized in 34 countries; the US Food and Drug Administration is expected to make its decision on its bladder cancer label expansion by January 6, 2027. Overseas commercialization and indication expansion remain key focuses for the company's product development.

3. As of June 30, BlackRock increased its IBRX holdings by 7.74 million shares to 34.08 million shares, and Vanguard Group-related entities collectively increased holdings by 2.43 million shares to 36.48 million shares. Two Sigma’s holdings increased by 153%. Institutional shareholding disclosure has become one of the recent triggers for share price attention.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)